Gompf's Antibiotics Redux

A Pocket Tool for the Medical Student, or Resident on the Infectious Diseases Clinical Rotation

or

Just about anyone who could use a pocket antibiotic tool

By

Sandra G. Gompf, MD Professor, Infectious Diseases University of South Florida Morsani College of Medicine Tampa, FL

Updated APR 2023



Gompf's Antibiotics Redux by Sandra G. Gompf, MD is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Made in the United States of America.

ANTIBIOTIC PEARLS

1. Penicillins generally cover Gram +s, anaerobes, certain Gram -s depending on the antibiotic.

2. Cephalosporins generally cover Gram +s (EXCEPT Enterococcus!), Gram –s, few or NO anaerobes. ONLY ceftazidime/cefepime cover Pseudomonas. They do not cover SPACEK/SPICE* Gram negatives reliably; ceftriaxone/cefepime may be fine in less serious SPACEK/SPICE infections.

3. Aztreonam, a monobactam, covers <u>ONLY Gram -s</u>, incl. Pseudomonas. Reserve for beta lactamallergic patients.

4. Aminoglycosides generally cover Gram +s (except tobramycin) & Gram –s, NO anaerobes, some Mycobacteria.

 Quinolones cover Gram –s best (<u>except moxifloxacin/delafloxacin</u>, which are "respiratory quinolones" most active against Gram +s & anaerobes), some Mycobacteria.

6. Sulfas generally cover some Gram +s/MRSA, Nocardia, Listeria, Pneumocystis, most Gram –s except Pseudomonas.

7. Clindamycin generally covers Gram +s, incl anaerobes except Clostridia, like anaerobic/microaerophilic Strep/Peptostrep, Actinomyces (better for infections above the diaphragm).

8. Metronidazole generally covers anaerobes like Bacteroides, Prevotella, Clostridia; +/-Peptostrep (better for infections <u>below the diaphragm</u>).

9. Carbapenems are Big Gun Beta Lactams & Expensive. Use sparingly. Ertapenem covers most organisms except Pseudomonas. Imipenem, meropenem, & doripenem include Pseudomonas. Resistance in one carbapenem doesn't predict resistance in others.

10. A word about Enterococcus! Enterococcus in well-defined polymicrobial infections (cholecystitis, GI perforation, decubitus infections) tends to be somewhat of an opportunist & clears once source control is achieved, even if it spills into blood). Isolated Enterococcus faecalis/faecium bacteremia or hematogenous infection (septic arthritis, vertebral osteomyelitis, endocarditis, "community-acquired" bacteremia without an immediately source) should raise as much concern as Staphylococcus aureus. In that setting, even if reported as very ampicillin/penicillin-susceptible, and ampicillin is considered "drug of choice", know that these organisms have *lower*-affinity penicillin/penicillin/penicillin should be considered bacterio-STATIC. Synergistic combination therapy is preferred for these infections, such as amp + gentamicin. Amp + ceftriaxone/ceftaroline is increasingly preferred due to nephrotoxicity with gent & gent resistance. The combination of these beta lactams binds more PBPs that ampicillin alone & lowers the ampicillin MIC. In addition, know that vancomycin is bactericidal for most GPCs *except Enterococcus* (bacterio-STATIC).

Shameless plug:

Visit <u>www.gompfsidpearls.net</u> for more regularly updated ID clinical tools & links I find useful in practice.



Do's & DON'Ts

- 1. Don't use an antibiotic if you don't need to.
 - If a bacterial infection is not high in the differential and the patient is not clinically toxic, forgo antibiotics. They are poor antipyretics.
- 2. Persistent fevers require <u>work-up</u>, not more antibiotics.
 - If you are treating with broad antibiotics and fevers persist, stop them; they aren't helping.
 - Look for undrained foci of infection/pus → drain it.
 - $\succ \quad \underline{\text{Look for non-infectious cause}} \rightarrow \text{treat it.}$
 - ➤ True FUO in a rapidly deteriorating patient may warrant empiric anti-TB therapy → Call ID.
- 3. DO use an oral antibiotic when you can; use one narrow antibiotic when you can; <u>stop</u> antibiotics when you can.
 - Antibiotics are not cheap; switch to PO when reasonable.
 - Two antibiotics don't always prevent resistance better than one, and neither do broad spectrum drugs. More drugs = more resistance.
 - But NEVER give Rifampin alone! Rapid high-level resistance occurs.
 - o TB/Atypical mycobacteria: NEVER use 1 drug in active TB
 - DON'T treat viral infections (or noninfectious syndromes) with antibiotics beyond the point at which you have ruled out bacterial infection.
- 4. Don't combine 2 of the same class of antibiotics (e.g. 2 beta lactams, 2 quinolones) unless you have data or your friendly neighborhood ID specialist to back it up. They may unpredictably antagonize, synergize, or double the adverse effects. E.g. Clindamycinrifampin combo dramatically reduces clindamycin serum concentration. [https://doi.org/10.1016/j.jinf.2015.03.013; http://dx.doi.org/10.1684/ejd.2013.2213]

5. Always monitor for antibiotic adverse effects.

- Antibiotics are a double-edged sword. Respect them.
- Watch for hypersensitivity/bone marrow suppression/interstitial nephritis/hepatotoxicity/drug fever with beta lactams, acute tubular necrosis/irreversible ototoxicity with aminoglycosides, & Clostridium difficile with almost all of them.
- Watch for yeast overgrowth/Candidemia with prolonged/multiple antibiotic therapy.
- C. diff. is easy to miss in 2 situations:
 - Colostomies stumps/small bowel can be infected with C.diff.!
 - Spinal cord injured patients unexplained abdominal distension & leukocytosis are a clue
- RIFAMPIN REDUCES EFFECTIVENESS OF ORALCONTRACEPTIVES! Tell female patients to add barrier contraception until the next new pill pack after finishing antibiotics.

Antifungal coverage in general:

fluconazole = Cryptococcus, Coccidioides, dermatophytes, Candida EXCEPT Candida krusei/auris/some glabrata and all molds; high CSF/urine levels

itraconazole = Candida, Histoplasma, Crypto, Cocci, Aspergillus, Sporothrix, Paracocci, Talaromyces voriconazole = Candida, Histo, Crypto, Aspergillus (except a few rare species, Fusarium, NOT initially for Mucor/Rhizopus, but OK as step-down after ampho B/source control; good CSF/poor urine levels posaconazole = same as vori, + Mucor/Rhizopus; variable CSF levels

isavuconazonium 372mg (= isavuconazole 200mg) = same as posa, some Mucor, INFERIOR to caspofungin for candidemia; few drug interactions; poor CSF/urine levels

enchinocandins (caspofungin/micafungin/anidulafungin) = Candida incl C. auris, Aspergillus, SOME Cryptococcus, NOT Fusarium/Mucor/Rhizopus/Trichosporon, NOT Histo/Blasto/Coccidioides; poor levels in CSF/urine/vitreous humor

amphotericin B = all, +/- Fusarium, NOT Candida lusitaniae (variable)/guillermondi/auris, NOT Scedosporium (Pseudallescheria), Lomentospora (Scedosporium); Aspergillus terreus flucytosine (5-flourocystosine) - increases penetration of above drugs, rapid resistance alone; good CSF/eve/urine levels

Fusarium: Vori 6mg/kg IV Q24H or 300mg PO x 1 d, then 4mg/kg/d IV or 200mg PO BID + Ampho B 1.2 mg/kg/d or ABLC 5mg/kg/d

Mucor: Ampho B 1.5mg/kg/d or liposomal ampho B or ABLC 5mg/kg/d + posaconazole/isuvaconazole (active metabolite of isuvaconazonium); NOT other azoles/enchinocandins

BacteriCIDAL vs. BacterioSTATIC

A consideration in choosing treatments for serious infection like severe sepsis, bacteremia, meningitis, pneumonia, endocarditis, neutropenic fever. A "cidal" drug kills quickly; a "static" drug slows or stops replication and/or toxic production. Whether it matters is somewhat controversial.

Beta lactams are CIDAL and penetrate tissues and inflamed meninges well. They are preferable in serious infection, including bacteremia, endovascular infection, CNS infection, and streptococcal cellulitis. Their microbial action is *time-dependent*, meaning that they are most effective the longer the concentration of drug in the affected site remains above the MIC of the bacteria. Thus, they can be dosed by *continuous or extended infusion*, which may also facilitate home & hemodialysis dosing. (UpToDate has a helpful chart; most drug databases like ePocrates, etc, don't offer alternative dosing recommendations.) Ceftazidime, cefepime, and ertapenem are stable enough to be given 3 times a week after hemodialysis. Ampicillin is stable at least 24 hrs for extended and continuous infusion.

Extended Spectrum Beta Lactamase (ESBL)-Producing Gram Negative Bacilli: It's complicated.

SPICE/SPACE/KEC are mnemonics for bacteria that either have *intrinsic* (chromosome-based, aka "constitutive") and/or *inducible* beta lactamases (chromosome- OR mobile genetic element/plasmid-mediated beta lactamases).

These organisms may all demonstrate resistance to commonly prescribed beta lactams and may require carbapenem* treatment. In addition, *inducible* beta lactamases may become reversibly derepressed (or "switched on") upon 1-7 days' exposure to a beta lactam and result in treatment failure.

Bottom Line Up Front: If suspecting sepsis, use ceftolozane-taz, ceftaz-avibactam, meropenem, or piperacillin-taz if MIC <16mg/L^{**}; otherwise, can deescalate to cefepime if MIC \leq 1 mg/L if stabilized.

KEC – Grouped by Family Enterobacteriaceae with moderate-high risk of *inducible*, chromosomal beta-lactamase (AmpC, Group C, cephalosporinase)—KNOW that these may trick you by testing S to ceftriaxone/ceftazidime, \rightarrow R may be induced. Inducible beta lactamases may become reversibly de-repressed (or "switched on") upon 1- 7 days' exposure to a beta lactam and result in treatment failure. Cefepime is a weak AmpC inducer and stands up to hydrolysis by AmpC β -lactamase, so is generally a good choice if the organism is susceptible.

[Aside: Klebsiella pneumoniae & some E.coli often acquire a non-inducible, plasmid-based Group A beta lactamase (TEM) with a narrow spectrum against ampicillin & 1st-gen cephalosporins. Just be aware that this pattern comes up often in susceptibility testing & does not confirm or rule out an inducible ESBL.] Klebsiella aerogenes (formerly Enterobacter) Enterobacter cloacae Citrobacter freundii

SPACE/SPICE – **Treat based on susceptibility report and severity.** [These species' ampC mutations are *usually not inducible*, so these DO test R to ceftriaxone/ceftazidime, so *this mnemonic has fallen out of favor.*] **Consider:** Severity of infection (bacteremia, meningitis), high inoculum/source control (UTI/pyelonephritis vs endocarditis), presence of biofilm (infected device), & MICs to cefepime ($\leq 1 \text{ mg/L}$) & pip-tazobactam ($\leq 16 \text{ mg/L}$)** can help guide whether to use cefepime, pip-taz, or a carbapenem. Quinolones (bactericidal), trimethoprim-sulfamethoxazole (TMP-SMX), tetracyclines, and aminoglycosides are options if susceptible.

Presence of **chromosomal ("constitutive", "intrinsic") or mobile genetic element**-acquired (**plasmid**mediated) beta lactamases. Serratia/Salmonella/Shigella Proteus (non-P. mirabilis/"Indole +")/Providencia Pseudomonas Acinetobacter baumanii complex Citrobacter species Enterobacter complex (Yersinia enterocolitica – not enough data)

E. coli and Klebsiella are the most common ESBL producers, so many labs screen those isolates if MIC for ceftazidime is >/= 2 mg/L. Remember that **Klebsiella** almost all have a constitutive chromosomebased beta lactamase (usually SHV-1) & test R to ampicillin/ticarcillin.

*Note that carbapenems and the monobactam, aztreonam *are* beta lactams, as they *all* have a beta lactam ring. This may be confusing initially when you read about beta-lactam resistance and recommendations to use a beta lactam "versus" carbapenem; many articles gloss over this.

**<u>MERINO Trial 2018</u> suggested higher 30-day all-cause mortality with pip-taz vs meropenem, but <u>other</u> <u>trials</u> and <u>post-hoc</u> <u>analysis</u> <u>of</u> <u>MERINO</u> have suggested MIC > 16mg/L to pip-taz is responsible for the difference. If MIC is low, piperacillin-tazo may be acceptable as "carbapenem-sparing" in infections with source control (e.g. pyelonephritis without obstruction). See also <u>Impact of the MIC of Piperacillin-</u> <u>Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum-Lactamase Pro-</u> <u>ducing Escherichia coli</u>, 2013; <u>Association Between Minimum Inhibitory Concentration, Beta-lactamase</u> <u>Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO</u> <u>Study 10/27/2020; IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infec-</u> <u>tions: Version 2.0</u>, 3/31/2022.)

Carbapenem (CP) Resistant Gram Negative Bacilli:

(Carbapenem attached to the beta lactam ring is what preserves activity against ESBL.) Affects mainly **Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii (CRAB)**. May possess intrinsic vs mobile genetic element carbapenemase-encoding genes that inactivate enzymes, induce efflux pumps or limit porin channels. Carbapenems are not necessarily interchangeable.

Antibiotics for Resistant Gram + Cocci

- Vancomycin, teichoplanin (Europe) cover all but vancomycin-resistant Gram +s.
- Vancomycin is bacterioSTATIC against Enterococcus.
- Dalbavancin, oritavancin, televancin same mechanism as vancomycin & susceptibility generally correlates with vancomycin susceptibility; they add VRE, VISA/VRSA coverage.
- Daptomycin is bacteriCIDAL for both MRSA and Enterococcus & penetrates biofilm.
- Linezolid & tigecycline are bacterioSTATIC, NOT a choice for bacteremia unless no other options are possible, and not as monotherapy, unless you can cite legitimate supportive data.
- Tigecycline is difficult to tolerate due to 20% nausea/vomiting & associated with higher mortality than comparators for FDA-approved indications in after-market review of pooled clinical trials.
- All but vancomycin are EXPENSIVE & generally reserved for vancomycin-resistant Gram +s.

Pseudomonas, Acinetobacter, Stenotrophomonas vs other GNR

- These species are not of the family Enterobacteriaceae & often affect patients whose microbiome has been altered by extensive antibiotic/healthcare exposure.
- Acinetobacter are intrinsically resistant to multiple antibiotics and may be variably susceptible to carbapenems (susceptibility to one carbapenem does not predict susceptibility to another!).
- Stenotrophomonas are intrinsically resistant to carbapenemis; generally most susceptible to quinolones, sulfas, and tetracyclines.

Which antibiotics are bacterioSTATIC?

"In sepsis, restore Volume with a Liter of NML (normal) Saline."

Vancomycin in Enterococcus; cidal for all other GPCs Linezolid/Lefamulin Tetracyclines/Tigecycline Nitrofurantoin "MLS antibiotic group" – clindamycin, macrolides (Note: streptogramins are bactericidal) Sulfas/trimethoprim

Everything else is bactericidal.

Note bene: Clindamycin is used as an *adjunct* for Staph or Strep toxic shock, severe streptococcal cellulitis or suspected necrotizing infection; it *halts protein synthesis*—i.e stops production of toxins that mediate severe inflammation, necrosis, and toxic shock. Many Staphylococcus aureus strains carry *inducible* clindamycin resistance genes, so I suggest having susceptibilities available before relying on clindamycin alone for this pathogen (if your lab doesn't report inducible clindamycin resistance, check for erythromycin resistance*erm* mutation! ---as a clue). You can also use other drugs whose mechanism of action is disruption of protein synthesis: linezolid, doxycycline/minocycline/tigecycline for toxininhibition in severe Staph infection.

What does the MIC mean & how do we use it?

The MIC is the lowest concentration of an antimicrobial agent that completely prevents visible growth of the test strain of an organism in culture. Each antibiotic will have a different MIC for each organism. The MIC value of an antibiotic must be compared with clinical outcomes for the disease caused by a given organism; in some cases, this is further drilled down to differentiate between clinical scenarios (e.g., meningitis vs UTI), and the pharmacokinetics of individual antimicrobials. This overview yields "*clinical breakpoints*" that define whether the strain is susceptible (S), susceptible dose dependent (SDD) or resistant (R) to the antibiotic. Clinical breakpoints are internationally reviewed & and adjusted yearly according to expert consensus, epidemiology, and clinical literature by EUCAST (European Committee on Antimicrobial Susceptibility Testing), the American CLSI (Clinical and Laboratory Standards Institute), and further updated by the FDA (Food and Drug Administration). Fortunately, your friendly hospital Micro lab and their automated systems do a LOT of the interpretation work for you. If Micro says it's susceptible, it usually is—just beware of SPICE/CEK (d). And vancomycin "MIC creep" with S. aureus bacteremia—as MIC "creeps" above 1, so does treatment failure. Etc, etc.

Pharmacokinetics & Pharmacodynamics (PK/PD)

Important determinants of antibiotic dosing for maximal effect include time-dependent vs concentration-dependent activity, volume of distribution/Vd (obesity, serum albumin), and route of elimination (renal, hepatic [cytochrome P450 enzymes], GI).

Time-Dependent antibiotics depend on duration of time that free antibiotic levels remain in tissue above MIC, no post-antibiotic effect. Doses must be given at regular intervals to maintain activity. Low albumin levels may lower free antibiotic levels by allowing increased free antibiotic to be cleared before it gets into tissues (highly protein-bound antibiotics may need higher doses, esp with less susceptible organisms).


All beta lactams, monobactam, carbapenems

Concentration-dependent antibiotics act by achieving a high initial concentration & have a persistent "post-antibiotic effect"—i.e. bacterial growth is inhibited or "stunned" for a long time even after concentrations are no longer above MIC. Allows for extended dose intervals. Low albumin levels may lower free antibiotic levels by allowing increased free antibiotic to be cleared before it gets into tissues. At higher doses, highly protein-bound antibiotics may maintain adequate serum concentration if enough free antibiotic is available; again, may need higher dose).

- Aminoglycosides
- Daptomycin
- Metronidazole
- Quinolones (mostly)

Combination of Time above MIC + Post-antibiotic Effect

- MLS group macrolides, clindamycin, tetracyclines
- Linezolid
- Vancomycin dosing is optimized by achieving certain concentration for certain period of time, or "area under the curve" (AUC) -based dosing



Highly bound (>70%)	Moderately bound (70-30%)	Minimally bound (<30%)
Amphotericin B (90%)	Azithromycin (7–51%)	Amikacin (0-11%)
Anidulafungin (>99%)	Aztreonam (60%)	Amoxicillin (17-20%)
Caspofungin (97%)	Cefotaxime (40%)	Ampicillin (15-25%)
Cefazolin (75-85%)	Cefuroxime (33-50%)	Cefepime (16-19%)
Cefonicid (98%)	Cephalothin (55-75%)	Ceftazidime (17%)
Cefoperazone (90%)	Ciprofloxacin (20-40%)	Ceftobiprole (22%)
Cefoxitin (80-50%)	Clarithromycin (42-50%)	Cefpirome (9%)
Ceftriaxone (85–95%)	Chloramphenicol (60%)	Colistin (<10%)
Clindamycin (90% bound to a1-acid glycoprotein)	Levofloxacin (50%)	Doripenem (8%)
Cloxacillin (94%)	Linezolid (31%)	Ethambutol (20-30%)
Dalbavancin (93%)	Moxifloxacin (30-50%)	Fluconazole (11-12%)
Daptomycin (90-93%, 30% to a1-acid glycoprotein)	Nitrofurantoin (40%)	Fosfomycin (0%)
Dicloxacillin (97%)	Benzylpenicillin [penicillin-G] (65%)	Gentamycin (<30%)
Doxycycline (93%)	Piperacillin (30%)	Imipenem (20%)
Ertapenem (85–95%)	Sulfamethoxazole (68%)	Isoniazide (0-10%)
Erythromycin (73–81%)	Ticarcillin (55%)	Meropenem (2%)
Faropenem (96–99%)	Trimethoprim (45%)	Metronidazole (<20%)
Flucloxacillin (95%)	Vancomycin (30-60%)	Norfloxacin (10-15%)
Fusidic acid (95–97%)	Voriconazole (58%)	Polymyxin B (<10%)
Iclaprim (93%)		Quinupristin/dalfopristin (11-26%
Itraconazole (99.8%)		Tobramycin (<30%)
Lincomycin (80–90%)		
Minocycline (75%)		PO cefpodoxime (18-30%)
Nafcillin (90%)		
Oxacillin (93%)		
Posaconazole (>97%)		
Rifampicin [rifampin] (80%)		
Sulfisoxazole (92%)		
Teicoplanin (90–95%)		
Telavancin (92–94%)		
Tigecycline (71-89%)		

© 2011 Adis Data Information BV. All rights reserved.

Clin Pharmacokinet 2011; 50 (2)

THE CLASSES (not an exhaustive list)

DRUG	is are CIDAL, good tissue pen	USES	TOXICITY	Cerebral
				Spinal Fluid (CSF)
penicillin G \$ CIDAL	Group A Strep (no re- sistance) Strep viridans Neisseria Capnocytophagia Actinomyces Fusobacterium Clostridia perfrin- gens/tetani Pasteurella Treponema/ Leptospirosis NOT Staph aureus (re- sistant)	Skin/soft tissue (SST) or mouth infec- tions	Hypersens- itivity Stevens Johnson Interstitial nephritis Seizures (if high level) Bone marrow suppress-ion C.difficile	
AminoPCN \$\$ amoxicillin* ampicillin* amox/clav amp/sulbactam CIDAL	Add to the above: Listeria MSSA Most Pneumococcus Proteus Hemophilus influ. (beta lactamase negative) Salmonella/Shigella Anaerobes * <i>Klebsiella are intrinsical- ly resistant to amp/amox</i> (clavulanate/sulbactam don't add much activity) Note: High-dose amp- sulbactam may used as a source of <i>sulbactam</i> in treating MDR Acinetobac- ter	Otitis media Sinusitis SST Meningitis in elderly	Above	YES if inflamed
CarboxyPCN \$\$ ticarcillin/clav (Europe) piperacillin piperacillin/tazobactam CIDAL	Adds to the above: Pseudomonas Enterobacteriaceae* Stenotrophomonas (ticar) Gut anaerobes MSSA Pip & Pip/tazo more potent for GNRs & more resistant to AmpC/ESBLs (See "SPICE" above) * Klebsiella is intrinsically R to ticarcillin	Adds to above: Gut/ surgical infec- tions Nosocomial pneumonia Prostate Osteomyelitis	Above	

Penicillins - beta lactams are CIDAL, good tissue penetration

Cephalosporins – Think of progressive broadening of spectrum from Gram + to Gram - with each generation. Beta lactams are CIDAL. [\odot = can be dosed 3 times weekly in dialysis patients] ***CROSS-ALLERGY (same side chains) between aztreonam – ceftazidime – cefiderocol***

DRUG COVERAGE USES TOXICITY CSF	
---------------------------------	--

1 st Generation \$\$ cephalexin PO cefadroxil PO cefazolin IV/IM CIDAL	GPC/MSSA/streptoco cci, E. coli, Proteus, some Klebsiella (in- creasingly ampC+/ESBL) NOT Enterococci	SSTI Uncomplicat- ed/Non-diabetic osteomyelitis PreOP prophylaxis	Hypersensitivity Bone marrow suppression Diarrhea C.difficile	POOR
2 nd Generation \$\$ cefuroxime (IV/PO) cefaclor (PO) Cefamycins: cefoxitin (IV) cefotetan (IV) 3 rd Generation \$\$ Cefpodoxime (PO) ceftriaxone (IM/IV, QD dosing) cefotaxime (IV) CIDAL	Streptococci, uncom- plicated MSSA Pneumococcus Neisseria Some GNR except Pseudomonas Cefamycins are the only ones that relia- bly cover anaerobes NOT Enterococci Above; covers viri- dans streptococci, pneumococcus, but reduced PBP binding in MSSA	Community ac- quired pneumonia (CAP) meningitis OM/sinusitis Gonorrhea Most community- acquired infections Gonorrhea Pyelonephritis Best <i>PO</i> ceph for GU is cefpodoxime (20-30% protein- bound, vs PO cefdinir, which is poorly excreted in urine & up to 70% protein-bound)	Hypersensitivity RASH/Stevens Johnson w/ cefaclor High INR/PT w/ cefoxitin/ cefotetan Bone marrow suppression C.difficile Above Ceftriaxone: <i>Pseudo- cholelithiasis</i> (biliary sludge)	YES if strongly inflamed ceftriaxone >90% protein bound, low BBB penetration
4 th Genera- tion/Anti- pseudomonal	Above, plus Pseudo- monas More resistant to beta	Above, plus neu- tropenic fever	Above Cefepime: Encephalopathy,	
\$\$ ceftazidime (IV) © cefepime ©	lactamases/ESBLs (See "SPICE" above) because it is not porin-dependent		non-convulsive status epilepticus	
CIDAL	NOT Enterococci			

5 th Genera- tion/Anti-MRSA \$\$\$ ceftaroline CIDAL Advanced- generation/Anti- pseudomonal	Similar to 3 rd genera- tion, plus MRSA, VISA/VRSA/VRE faecalis (NOT E. faecium), pneumo- coccus, beta-lactamase + H.flu, Moraxella Listeria NO Pseudomonas Viridans streptococci NOT Enterococci or Staphylococci	Complicated SSTI, CAP (NOT MRSA- insufficient data) Complicated UTI/pyelo Complicated in-	Above Above Nausea, diar- rhea, headache,	
ceftolozane- tazobactam ceftazidime- avibactam	ceftoloz-taz covers GNRs incl Pseudo- monas, ESBLs, <i>some</i> carbapenemase- producing P. aeru- ginosa (CRPA), NOT KPC+	traabdominal infec- tion ceftaz-avi adds HAP	fever, renal insufficiency (ceftolaz-taz)	(%
CIDAL	ceftaz-avi covers ESBL & KPC+ car- bapenemase (1 st line agent) ceftaz-avi covers GNRs incl Pseudo- monas, adds cover- age for ceftaz-R, ESBLs, some ampC- R, <i>some</i> car- bapenemases (NOT metallobetalactama- se)			erita: kili memeri (mameri memeri) 20.57: Y.S. - 90% mala screterion unchange (avbacram 97%) 10% protein bound eribbazm 5.9% memeri (m. unchanged - 30% protein bound - 30%
cefiderocol CIDAL Similar side chains of both cefep & ceftaz Trojan horse siderophore: Chelates Fe++, so drug is actively transported with Fe++ via sidero- phore channels	Reliably covers XDR/carbapenem-R: Metallobetalactamase producers (MBL) Klebsiella pneumo- niae (KPC+) Pseudomonas aeru- ginosa (CRPA) Enterobacteriaceae (CRE) Acinetobacter bau- manii (CRAB) Stenotrophomonas Burkholderia cepacian NO GPC!	Complicated UTI/pyelo HAP	Hypersensitivity Bone marrow suppression Diarrhea C.difficile <u>Unclear if higher</u> <u>all-cause mortali-</u> ty in critically ill with carba-R <u>GNB (CREDI- BLE-CR trial)</u>	CSF POOR 58% protein bound 60-70% renal excretion, unchanged

Monobactam

DRUG	COVERAGE	USES	TOXICITY	CSF
aztreonam	ONLY GNRs, incl Pseudomonas	GNR infections; NOT a replacement	Low	YES if in- flamed
\$\$	Covers metallobeta-	for all aminoglyco- side uses (no syn-	Good alternative for beta lactam	[Modal J et al. AAC.
CIDAL	lactamase car- bapenemases, but not ESBL (resistance usually occurs to- gether)—combination of aztreonam + ceftaz-avibactam might be used in salvage cases (<u>CID</u> <u>2021;72:1871</u>)	ergy for GPC, ŃO Enterococcal cov- erage)	allergies EXCEPT with ceftazidime, cefiderocol	1986;29:281- 3.]

1	Carbapenems (Reserved for Multidrug Resistant Organisms – MDRO)
	$[\odot = can be dosed 3 times weekly in dialysis patients]$

DRUG	COVERAGE	USES	TOXICITY	CSF
imipenem- cilastin meropenem- vaboractam imipenem- cilastin- relebactam \$\$\$	GPCs EXCEPT MRSA GNRs EXCEPT Stenotropho- monas/Burkholderia ESBL+ & "SPICE" GNRs Anaerobes (incl Cutibacterium) Listeria Pneumococcus Nocardia asteroides (NOT brasiliensis) Legionella Mycobacterium avium Enterococcus (NOT E. faecium) mero-vaboractam adds <i>car- bapenemase+ Klebsiella pneu- monia (KPC)</i> , class A carbap-R Enterobacteraciae (NOT metallobetalactama- se/OXA carbap-R, NOT carbap- R Pseudomonas/Acinetobacter) Relebactam is not active against Morganellacea group (Morganella, Proteus, Providen- tia)	Resistant GNR infections Serious gut infections Necrotizing pancreatitis	IV/IM Hypersensit- ivity (~10% cross- allergy with beta lactams) Seizures with imipenem (if renal insuffi- ciency or high levels used) Candida over- growth/ infections C.difficile	YES
doripenem \$\$\$ CIDAL	Above, possibly lower MICs to Pseudomonas & Acinetobacter	Above Higher mortality than imipenem in VAP	Above	
ertapenem © \$\$\$ CIDAL	Above, without Pseudomonas coverage	Postpartum uterine infec- tions Postsurgical Abdominal infections (not Pseudomo-nas)	Above Encephalo- pathy	

Aminoglycosides

DRUG	COVERAGE	USES	TOXICITY/ MISC	CSF
gentamicin streptomycin spectinomycin amikacin liposomal ami- kacin \$-\$\$\$ CIDAL	Gent: VSE/VRE/variable Staph, GNRs incl Pseudomonas Tobra/Amik: GNRs incl Pseudo- monas Amik: TB, non-TB Mycobacteria Strepto -Yersinia -MDR Mtb Gent/Strepto -Tularemia Spectino -Gonorrhea NO coverage for: Acinetobacter/Stenotrophomonas Anaerobes Pneumococcus	Synergy with beta lactams for GPC/Pseud- omonas infections Usually not used alone except for UTIs	IV/Aerosol Acute tubular necrosis (rever- sible) Cochlear toxici- ty (genetic predisposition) Vestibular toxicity (irre- versible) When possible: -stop after 3-5 d -use once-daily dosing -avoid in elderly Liposomal amik – hypersensitiv- ity pneumonitis, hemoptysis, bronchospasm, exacerbation of lung disease Neuromuscular blockade (may exacerbate myasthenia gravis & para- lytic agents)	NO or UNKNOWN (use intrathecal)
fosfomycin \$\$ CIDAL	Enterococcus Staph. aureus GNRs	Simple cystitis in women Off-label q3days for complicated or MDR GNRs, VRE if	PO only Above, signifi- cant diarrhea	
plazomicin \$\$ CIDAL	GNRs incl MDR/KPC/metalobetalact/CRE GNRs,variable Pseudomonas (use only if known susceptible), NOT Steno, Acinetobacter	susceptible Complicated UTI/pyelo	IV only Above Limited data	

Sulfonamides/Sulfas (INTRACELLULAR ACTIVITY)

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
trimethoprim- sulfamethoxazole co-trimoxazole \$ STATIC for Staph	Staph. aureus (incl MRSA) (NOT Enterococ- cus, Pseudomo- nas, Acinetobac- ter) Legionella Stenotrophomonas Listeria Pneumocystis Nocardia Burkholderia cepacia Moraxella Yersinia Francisella tula- rensis Toxoplasma Atypical mycobac- teria (<i>M. marinum</i>) Some common coliforms	UTI MRSA SSTI Specific agents at left	IV/PO RASH/Stevens Johnson Nausea Fever Bone marrow sup- pression Hemolysis (if G6PD deficient) Hepatotoxicity Elevated creatinine or K+ (competes with Cr for tubular secre- tion, blocks K+ ex- cretion) Kernicterus in neo- nates C.difficile Sun sensitivity	YES

Pleuromutilins (INTRACELLULAR ACTIVITY)

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
Lefamulin**	S. pneumoniae MSSA, ?MRSA	CAP/community- acquired pneu-	Nausea, hepato- toxicity, CNS	UNKNOWN 70% fecal excre-
IV/PO Protein synthesis	Hemophilus influenzae Mycoplasma	monia ** Bacteriostatic –	Hypokalemia	tion
inhibitor – multiple binding sites to ribosome, higher	pneumoniae Chlamydia pneu-	be aware of this when empirically	Prolonged QTc	
resistance barrier	moniae Legionella pneu-	treating serious infections.	Teratogenicity	
STATIC	mophila		C. difficile	

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
Macrolides	Pneumococcus IF local	LRTI/	IV/PO	
erythromycin	resistance is <25%	bronchitis		
clarithromycin	MSStaph. aureus (not	Sinusitis	Nausea/	
azithromycin	MRSA)	Dental/	vomiting	
ድድ	Legionella Listeria	oral infec- tions	Abdominal cramps/	
\$\$	Hemophilus	lions	diarrhea (Lowest with Azithro)	
STATIC	Moraxella	Atypical	C.difficile	dia
STATIC	Mycoplasma	mycobacteria	C.difficile	ň
	Pertussis	(incl MAC	Ototoxicity with chronic use	hla
	F enussis	prophy in	Ololoxicity with childric use	U U
		HIV)	Rare association with cardio-	ella
	Neisseria meningitis	1110)	vascular mortality with QTc	Ú
	_		prolongation, low Mg++/K+.	-eg
			protongation, for high met	a, L
	Chlamydia/Hemophylus		Interactions:	us
	ducreyi		Ery/Clari induce P450!	pla
				λco
	Campylobacter		Neuromuscular blockade with	Σ
	Helicobacter pylori		Ery (may exacerbate myas-	. fo
	Salmonella/Shigella		thenia gravis & paralytic	ttei
	Carriera, Crigona		agents)	ed.
				e I
	Bartonella			Adequate – better for Mycoplasma, Legionella, Chlamydia
	Borrelia burgdorpheri			fed
	(Lyme disease			Ac
	Babesia microti			
	Actinomyces			
	Atypical mycobacteria			
	A typical mycobactella			

Macrolides/Lincosamides (Macrolide-Lincosamide-Streptrogramin B class, or MSL—all bind 50s ribosome subunit & share resistance genes)

r	1	r		
Lincosamides	CIDAL for Group A	Severe SSTI,	IV/PO	
	streptococcus,	necrotizing	C.difficile!! (>30% develop it	
clindamycin	MSStaph. aureus	fasciitis,	on a week of clinda)	
-	(MRSA, but	MRSA	-	
\$\$	watch for inducible erm		Dysgeusia	
•••	resistance. Clue is	"Infections	,	
STATIC	resistance to erythro-	above the		
00	mycin)	diaphragm"	Rash, fever, eosinophilia	
		alapinagin	Erythema multiforme	
	Pneumococcus	Head and	-	
	Thedinococcus	neck/dental	Reversible neutro-	~
	Inhibits toxic proteins in	infections	penia/thrombocytopenia	f
	severe Strep A & S.	Lung ab-		POOR except for Toxoplasmosis in HIV
	aureus/	scess/	Watch for hepatitis/obstructive	<u>s</u>
	necrotizing fasciitis.	aspiration	jaundice, severe liver injury	so
	necrotizing fascilits.		J , J J	Ш
	Oral anaerobes: Gram	pneumonia	Neuromuscular blockade	las
		(tip: no teeth	(may exacerbate myasthenia	do
	+ such as Peptostrep-	= no anaero-	gravis & paralytic agents)	,ô
	to-coccus,	bes)	gravis a paralytic agents)	Ē
	Fusobacterium,			fo
	Prevotella,	Bacterial		ept
	Actinomyces, & Clos-	vaginosis		XCE
	tridial spp other than			Ð
	Clostridium difficile	Babesiosis		OR
				ŏ
		Toxoplasma		<u>a</u>
	Gram – such as Bac-	in HIV		
	teroides			
	(may not cover in up to			
	25% of cases or strains			
	with MIC >/= 8			
	mcg/mL)			
	·			
	Babesiosis			
	•	•		

Nitrofuran

DRUG	COVERAGE	USES	TOXICITY/MISC	CNS
nitrofurantoin	GNRs EXCEPT	Cystitis	PO only	
	Pseudomonas,	Susceptible		
\$	Proteus, and	ESBL GNRs	Nausea/	
	Enterococcus incl		vomiting	
CIDAL	susceptible VRE	ONLY reaches		
		therapeutic level	C.difficile	
		in URINE		N N
	Multiple sites of			NONE
	action, inhibits syn-			_
	thesis of DNA, RNA,			
	proteins, cell wall -			
	higher resistance			
	barrier than most			
	antibiotics			

Quinolones (Resistance is rising due to overuse; single-step mutation→ resistance may arise while on therapy; INTRACELLULAR ACTIVITY; high concentration in bone, prostate, CSF)

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
"Gram negative"	GNRs including	UTI/GU infection	IV/PO	
Quinolones	Pseudomonas	Intraabdominal	IV=PO (bioequiva-	
		infections	lent)	
ciprofloxacin	Levo covers	Endometritis	-	
levofloxacin	pneumococcus &		Dizziness/CNS	
norfloxacin	Stenotrophomonas	Hospital-	Diarrhea	
	well	associated lung	Нуро-	YES, HIGH DOSE
\$-\$\$		infections	/hyperglycemia	Ő
	"Atypical" pneu-		Sun sensitivity	μ Τ
CIDAL	monia:	Levo best for		Ō
	Mycoplasma,	acute sinusitis/	May exacerbate	I
	Chlamydia,	CAP	myasthenia gravis &	Ś
	Moraxella		paralytic agents	Ϋ́Ε
		Norflox: UTI only	(inhibits GABA	
	Some mycobacte-		receptors)	
	ria/TB		Max and an OT-	
			May prolong QTc (watch for palpita-	
			tions/syncope; avoid	
			if QTc > 500msec,	
			cardiomyopathy)	
			cardiomyopathy)	
			Rare spontaneous	
			tendon rupture	
			(watch for pain at	
			tendon sites)	
			,	
			*Aortic dissection	
			association*	
			C.difficile	
"Gram positive or	Pneumococcus,	CAP/community-	IV/PO	
Respiratory"	Streptococci,	associated	IV=PO (bioequiva-	UNKNOWN
Quinolone	Staphylococcus	respiratory infec-	lent)	
moviflovooin	(NOT MRSA)	tions Acute sinusitis	Above	
moxifloxacin	Legionella Gut anaerobes	Acute sinusitis	>60% <i>liver</i> excretion	
\$\$	Gui allaelopes	Intraabdom-inal		
ψψ	Atypical myco-	infections		
CIDAL	bac/TB	SSTI		
"Gram positive or	Streptococci,	SSTI	IV/PO	
Respiratory"	Staphylococcus	CAP/community-	IV=PO (bioequiva-	UNKNOWN
Quinolone	MRSA	associated	lent)	
	Pseudomonas	respiratory infec-		
delafloxacin	Legionella	tions	Above	
	Gut anaerobes	-		
\$\$				
	Atypical myco-			
CIDAL	bac/TB			

Nitroimidazole

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
metronidazole	Gram – anaerobes	"Infections below	IV/PO	
	incl. Bac-	the diaphragm"	Disulfiram-like	YES
\$\$	teroides fragilis	Intraabdominal	reaction (vomit-	
	and all Clostridia	abscess, peritonitis,	ing) if ethanol	

CIDAL	Entamoeba coli	diverticulitis, etc Endometritis/ Bacterial vaginosis Clostridium difficile colitis Entamoeba liver abscess/ dysentery	consumed within 3 days of therapy Aseptic meningi- tis/ neuropathies, rare	
		dysentery NOT to be given alone for lung ab- scess/ENT infec- tions		

Tetracyclines/Glycylcycline (INTRACELLULAR ACTIVITY)

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
Tetracyclines	MRSA/MSSA Pneu-	Acne/rosacea	IV/PO	
	mococcus. +/- GAS	SSTI	Discoloration of	YES (neurobo-
Minocycline	E. coli	CAP, esp	permanent teeth in	relliosis, syphilis)
Doxycycline	Legionella	under age 40	children	, - , 1 ,
	N. meningitidis	Dog/cat bite		
\$	Hemophilus	prophy as	Esophageal ulcer	
	Moraxella	alternative to		
STATIC	Mycoplasma	amox/clav	Hepatotoxicity	
	Chlamydia	Tickborne		
	Listeria	diseases	Pseudotumor	
	Brucella		cerebri, esp mino-	
	Actinomyces		cycline! (watch for	
	Borrelia burgdorferi		headache)	
	Rickettsia			
	Vibrio		Sun sensitivity	
	Treponema			
	Anaerobes: Fusobac-		C.difficile	
	terium, Cutibacterium,		labibit linenebae	
	Peptostreptococcus, Clostridium, some		Inhibit lipopolysa- ccharide-induced	
	Bacteroides fragi-		proinflammatory	
	lis/melanogenicus		products	
Glycylcycline	Above, plus	SSTI	IV only	
Ciyeyieyeinie	Staph. epidermidis	Intraabdo-inal	Above	UNKNOWN
tigecycline ±**	Enterococci	infections	7.0000	onationn
\$\$	Corynebacterium	CAP/HAP	20% tige, 6.5%	
**	N. gonorrhea		erava - nausea,	
	ESBL + E.coli/Klebs	Severe	vomiting	
eravacycline*	(NOT KPC)	C.difficile	Ŭ	
omadacycline	Stenotrophomonas	Y alveolar, soft	Inhibit lipopolysac-	
	Acinetobacter	tissue, bile/gut	charide-induced	
sarecycline	Salmonella	entry	proinflammatory	
(acne only)	B. fragilis/		products	
STATIC	anaerobes	Poor bone/joint,		
SIANO	Clostridia incl.	CNS	*/**	
	C.difficile	** Destariastat	Ampicillin/	
	NOT Decudemence	** Bacteriostat- ic – be aware	Amoxicillin CIDAL-	
	NOT Pseudomonas, Burkholderia	of this when	preferred in VRE that is amp-	
	Durkholuena	empirically	susceptible.	
	*eravacycline adds	treating serious	Susceptible.	
	ESBL, carbap-R	infections.		
	Acinetobacter	+ Increased		
		mortality vs.		
		comparators in		
	1	after-market		
	1	review of		
		pooled clinical		
		trials, incl in		
		FDA-approved		
		indications.		

Glycopeptides, lipoglycopeptides

DRUG	COVERAGE	USES	TOXICITY/ MISC	CSF
vancomycin \$ CIDAL except STATIC for Enterococci	Gram + cocci except VRE/VRSA <i>Most</i> Gram + rods (but see below) Corynebacterium Listeria C.diff (only PO) Increasing vanco- mycin MICs > 1 assoc with treat- ment failures ("MIC creep") Instrinsic re- sistance in: Leuconostoc Lactobacillus Propionobacterium Pediococcus Erysipelothrix Clostridia(non-diff.)	SSTI due to MRSA HAP/CAP due to MRSA Infections due to VRE	Vanc IV≠PO – PO not absorbed from gut Vanc requires a central IV line , due to phlebitis (which may cause fevers, unnecessary antibiot- ics/cultures/increased lengths of stay) "Red man syndrome" with vanc (histamine release) if infused too rapidly—infuse over 1-2 hours Leukopenia Thrombocytopenia Rare interstitial necrosis Ototoxicity (abrupt, irre- versible, usually elderly) Rarely, DRESS	YES
dalba- vancin \$\$\$	MSSA, MRSA, Group A, B strep- tococci, Strep anginosus group	SSTI, osteomyeli- tis/prosthetic joint infection, endocarditis, bloodstream infection 1500mg IV x1 OR 1000mg IV then 500mg in 7 days	Nausea, headache, diar- rhea Hepatotoxicity "Red man syndrome" with vanc (histamine release) if infused too rapidly—infuse over 1-2 hours	
televancin \$\$\$	MSSA, MRSA/VISA/VRSA , Group A, B strep- tococci, Strep anginosus group, VSEnterococcus	SSTI HAPneumonia due to MRSA/VISA	N/V, foamy urine Nephrotoxicity QTc prolongation Mortality > with mod/sev renal impairment com- pared with vanco Possibly teratogenic— avoid in pregnancy unless maternal benefit exceeds fetal risk "Red man syndrome" with vanc (histamine release) if infused too rapidly—infuse over 1-2 hours	

			Interferes with coag tests but not coagulation
oritavancin \$\$\$ CIDAL including Enterococci	MSSA, MRSA, Group A, B, C streptococcus, Streptococcus anginosus group, VSEnterococcus	SSTI **FAILED for osteo- myelitis** 1200mg IV x1, over 3 hr	Headache, N/V "Red man syndrome" with vanc (histamine release) if infused too rapidly—infuse over 1-2 hours Hepatotoxicity Artificially prolong PT/INR for up to 12 hr (5.1); aPTT for up to 12 hr (5.1); aPTT for up to 12 hr and ACT for up to 12 hr and ACT for up to 24 hr—Use Fac- tor Xa assay for coagula- tion testing Coadministration with warfarin may result in higher exposure of warfa- rin and increase risk for bleeding; monitor fre- quently for signs of bleed- ing

Cyclic Lipopeptides

DRUG	COVERAGE	USES	TOXICITY/ MISC	CSF
daptomycin	All Gram + cocci incl. Vanc-/Amp-	SSTI Bacteremia	IV only	UN-
\$\$\$\$	resistant* Entero- coccus	Osteomyelitis, Joint infections	False Prothrombin	KNOWN
CIDAL	MRSA/VRSA	May be active in	Time prolongation	
		biofilms (which usually inactivate antibiotics)	Nausea/vomiting Rhabdomyolysis & associated renal insufficiency (weekly creatinine, CPK)	
			Rare asthmatic pul- monary eosinophilia	
			NOT for primary pneumonia because it is inactivated in alveolar fluid, BUT seems effective in embolic lung infec- tion/septic emboli due to Gram +s, since the infection is more parenchymal.	
			*ampicillin/ amoxicillin (CIDAL) preferred in VRE that is amp-susceptible.	

Streptogramins

DRUG	COVER-AGE	USES	TOXICITY/ MISC	CSF
quinupristin-	Vanc-/Amp-	SSTI/non-MRSA	IV only	
dalfopristin	resistant*			UNKNOWN
-	Enteroco-ccus	Bacteremia	Needs central IV line	
\$\$\$\$	faecium MSSA	Endocarditis due to VRE faecium	due to frequent pain, phlebitis, fever	
CIDAL	Group A Strep			
		Extremely limited	>30+% Myalgias/	
	NOT Entero-	use.	Arthralgias	
Discontinued	co-ccus fae-		Nausea/	
	calis or MRSA		Vomiting/	
by Pfizer			Diarrhea	
2022			*ampicillin/	
			amoxicillin (CIDAL)	
			preferred in VRE that	
			is amp-susceptible.	

Oxazolidinone (INTRACELLULAR ACTIVITY)

DRUG	COVER-AGE	USES	TOXICITY/ MISC	CSF
linezolid \$\$\$\$ STATIC except CIDAL for streptococci	All Gram + cocci incl. ** vanc-/amp- resistant* Entero- coccus MRSA/VRSA TB/Atypical myco- bacteria Binds 23S rRNA- blocks formation of 50s/70s ribosomal initiation complex	SSTI MRSA HAP/CAP due to MRSA Osteomyelitis/ Joint infections (good bone pene- tration) **NOT for bactere- mia without a well- defined and remov- al or draining focus, NOT for endovas- cular infections	IV=PO (bioequivalent) Nausea/ vomiting/ diarrhea Temporary tooth staining Headache Thrombocytopenia/ Neutropenia after 7 days Peripheral/ Optic neuropathies with extended use Lactic acidosis (nausea, fatigue) Serotonin syndrome: Avoid high tyramine food/drink, SSRIs (> 100mg tyramine per meal). E.g. aged cheeses, dried/processed meats, ethanol, sauerkraut, soy sauce, or yeast ex-tract/supplements, ferments */**ampicillin/amoxicillin (CIDAL) preferred in VRE that is amp-susceptible. **Associated with treat-ment failure in bactere-mia, incl line & endovascu-	GOOD Myrianthefs et al. Serum and CSF concentrations of linezolid in neurosurgery patients. AAC 2016. 50(12): 3971-6.
tedizolid \$\$\$\$ STATIC	All Gram + cocci incl. ** VRE, Amp- resistant* Entero- coccus, MRSA/VRSA Binds 50s riboso- mal subunit	SSTI	Iar infections. IV=PO (bioequivalent) 6 days tedizolid Qdaily = 10 days linezolid BID = higher lipid solubility/higher tissue levels Nausea/headache/diarrhea Lower thrombocytopenia than linezolid; similar neuropathic events; no longer term data Serotonin syndrome: Avoid high tyramine food/drink (> 100mg tyramine per meal). E.g. aged cheeses, dried/processed meats, ethanol, sauerkraut, soy sauce, or yeast ex- tract/supplements, ferments	NO DATA – suspect similar to linezolid

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
colistin polymixin B colistimethate \$\$\$ CIDAL	Gram - including Pseudomonas, Acinetobacter membrane disrup- tion, binds lipopoly- saccharide (LPS)/ Gram - endotoxin	Intraabdominal infections UTI/GU infections Pneumonia/ Hospital-associated respiratory infections Potent anti-LPS binding/ neutralizing activity	IV/Aerosol 30% Nephrotoxi- city! Peripheral/ Optic neuropa- thies Neuromuscular blockade (may exacerbate my- asthenia gravis & paralytic agents)	YES

Colistin/Polymixin B (Reserved for multi-drug resistant organisms - MDRO)

Rifamycins

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
rifampin \$-\$\$ Only rifampin is discussed here, in con- text of use outside of mycobac- terial infec- tions CIDAL	Very broad, incl GPC/GNR, myco- bacteria; use is condition-specific RAPID RE- SISTANCE if given alone – Use in combinations Inhibits DNA- dependent RNA polymerase	Only used alone as prophylaxis against Neisseria meningitidis (2 days), Hemophilus influenza b (4 days) in contacts/nasal carriage Combination treatment in serious S. aureus, Streptococcal infec- tions Combination treatment of Legionella, Anthrax, Brucella, Bartonella, Anaplasma, Ehrlichia Combination treatment of tuberculous and non-tuberculous Myco- bacteria	IV/PO Red urine, sweat, tears, saliva – hold soft contact use Nausea, abd pain Hepatotoxicity (avoid ethanol & hepatotoxins), hyper-bilirubinemia Type I & Flu-like hypersensitivity Autoimmune reac- tions Many drug interac- tions – always check an updated reference	YES

References:

https://pubmed.ncbi.nlm.nih.gov/

http://webedition.sanfordguide.com/

www.drugs.com

www.emedicine.medscape.com

www.epocrates.com

www.micromedix.com

Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011 Feb;50(2):99-110. <u>doi: 10.2165/11539220-00000000-00000</u>. PMID: 21142293.

Acknowledgment:

Gratitude for support of my teaching efforts is owed to my alma mater, the University of South Florida Morsani College of Medicine Division of Infectious Diseases and International Medicine, and my distinguished professors there. I remain honored and very humbled to call them my colleagues these several years. I strive always to measure up to their high standards.

The opinions and information presented in any of my teaching materials, in print or electronically, remain my own intellectual property, and do not reflect the opinions or representations of any employer(s) or professional affiliates of which I am a part, past or present.

Thank YOU, dear Colleague, for your dedication to the Art and Science of Medicine. I hope that you find this tool of help in your care of the VIP at the center of our efforts:

The Patient.

Dr. G